NP 001 - UbiVac

Drug Profile

NP 001 - UbiVac

Alternative Names: NP-001 - UbiVac

Latest Information Update: 20 Nov 2015

Price : $50

At a glance

  • Originator UbiVac
  • Class Immunotherapies; Vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer; Human papillomavirus infections

Most Recent Events

  • 29 Oct 2015 Preclinical trials in Cancer in USA (Parenteral) before October 2015 (UbiVac pipeline, October 2015)
  • 29 Oct 2015 Preclinical trials in Human papillomavirus infections in USA (Parenteral) before October 2015 (UbiVac pipeline, October 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top